Amgen submits evolocumab MAA

Amgen Inc. (NASDAQ:AMGN) submitted an MAA to EMA for evolocumab ( AMG 145), a human mAb against proprotein convertase subtilisin/kexin type 9 (PCSK9), to treat high cholesterol. The application -- the first in the EU for a PCSK9 program -- comes on the heels of the submission last week of a BLA to FDA for evolocumab. Amgen was down $1.42 to $137.96 on Tuesday. ...